|
|
Profile
|
Delegates :
Yoshihiko Kitaura |
|
Incorporated :
June 3 , 2009 |
Paid in Capital :
7 Million yen |
Employees :
4 人 |
Address :
2-Chome 49-12, Himuro-cho, Takatsuki city OSAKA
〒56-1141
|
TEL/FAX :
81-72-628-1717 / 81-72-628-8469 |
URL：
http://yuimedic.com/index.html |
Attachment :
|
Mission/Background :
YuiMedic INC. is a drug discovery venture by former R&D members of a big Japanese pharmaceutical company, harnessing extensive experiences and strong expertise in drug discovery. We seek and identify novel biological targets for truly innovative drugs discovered in academia and national institutes. We discover promising candidate compounds for preclinical development, working on the novel drug target molecules. We focus on cancer and infectious disease areas. |
|
Technology & Business
|
LAT1 (L-Type Amino Acid Transporter1), cancer cell specific amino acid transporter, is playing a key role in amino acids supply to cancer cell. It is well known that expression of LAT1 correlates well with tumor malignancy. The candidate compound (small molecule), LAT1 inhibitor, showed in vitro growth inhibitory effect on MIAPaCa2 tumor cell and survival effect on the ip transplant MIAPaCa2 tumor in nude mouse at oral administration. No mouse acute toxicity was shown at high oral dose.
Clostridium difficile infection is a serious diarrheal illness associated with substantial morbidity and mortality. Patients generally have a response to oral vancomycin or metronidazole; however, the rate of recurrence is high. Two third of the deaths from diarrheal diseases in the United States were caused by c.difficile. A candidate compound (small molecule) is more potent than vancomycin and specific on in vitro antibacterial activity to c.difficile.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Ani-cancer drug
|
Preclinical
|
Mechanism of action is LAT1 inhibitor. Candidate compound showed survival effect on the ip transplant MIAPaCa2 tumor.
|
Preclinical studies
|
Antibiotics
|
Discovery
|
Candidate compound is more potent than vancomycin and specific on in vitro antibacterial activity to c.difficile.
|
in vivo studies using hamsters and oral acute toxicity studies in rats
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Since almost cancer cells express LAT1, combination chemotherapy with drugs whose mechanism of action is different from LAT1 would be useful. Companion diagnostic strategy can select responders prior to administration.
|
|
Alliance strategy
|
We are looking for a collaborator for trying preclinical studies regarding anti-cancer drug. We need fund for in vivo studies using hamsters and oral acute toxicity studies in rats regarding antibiotics to treat C.difficile
|
|
|